- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07834723
NIV-NAVA in Infants With Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial (NAVIGATE)
Non-invasive Ventilation With NAVA in Infants With Severe Bronchiolitis. A Multicenter Pilot Open Label Pragmatic Randomized Controlled Trial (NAVIGATE Trial)
Severe bronchiolitis is a common lung infection in babies that can cause serious breathing problems and often leads to hospitalization in pediatric intensive care units (PICUs). Many infants need special breathing support, usually through non-invasive methods like high-flow oxygen or continuous airway pressure. However, these methods don't always work, and about one in four infants end up needing a breathing tube (intubation), which comes with more risks and a longer recovery.
A newer breathing support method called NIV-NAVA (non-invasive ventilation with neurally adjusted ventilatory assist) may help. It uses signals from the baby's diaphragm to adjust the support in real-time, making breathing easier and possibly reducing the need for intubation. While early results are promising, no high-quality clinical trial has yet tested if NIV-NAVA is better than standard non-invasive support.
This study is a pilot trial - a small-scale version of a larger future study - happening in four PICUs across Canada. It will include 90 babies under 2 years old with severe bronchiolitis who need more support than standard methods provide. Half will receive NIV-NAVA, and half will receive the usual care.
The main goal of this pilot is to check if a larger trial is doable: Can we recruit enough babies? Can the PICU teams stick to the treatment plan? Can we collect the right information? The full study will eventually look at whether NIV-NAVA really lowers the number of babies who need intubation and improves recovery.
This research is led by a team of pediatric experts and could pave the way for better care for thousands of infants with severe breathing problems.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Goal(s) / Research Aims The primary objective of this multicenter pilot RCT is to determine the feasibility of a definitive multicenter RCT that will evaluate whether NIV-NAVA is superior to conventional NIV in infants with severe bronchiolitis who are not adequately supported by HFNC or CPAP. The primary hypothesis is that the pilot RCT will confirm the feasibility of the final trial.
Methods / Approaches This is an investigator-led, multicenter, randomized, controlled, open-label, pragmatic pilot trial conducted in four Canadian pediatric intensive care units (PICUs) with varying levels of experience with NIV-NAVA, supported by the Canadian Critical Care Trials Group (CCCTG).
Ninety infants younger than 2 years old who are admitted to the PICU with a clinical diagnosis of bronchiolitis, who require NIV support greater than CPAP/HFNC, and who have no exclusion criteria will be randomized 1:1 between NIV-NAVA and conventional NIV management.
The pilot trial's feasibility outcomes are the recruitment rate (the primary outcome), adherence to the intervention, and completion of the definitive trial's outcome measures. The primary outcome of the future definitive RCT is the intubation rate. Secondary outcomes will include respiratory distress evolution, comfort, duration of ventilatory support, PICU and hospital length of stay, nutrition and sedation, complication rates, post-PICU functional outcomes, carbon footprint, and cost-effectiveness analysis.
Expertise. An experienced, multidisciplinary team of senior, mid, and early career clinician scientists with unique expertise in pediatric NIV, trial methodology, pediatric respirology, and PICU research is leading this project.
Expected Outcomes. We expect this pilot trial to confirm the feasibility of a definitive trial on NIV-NAVA in severe bronchiolitis. As the first RCT in this understudied field, it will provide much-needed evidence on the most effective strategy for reducing intubation rates in infants with severe bronchiolitis.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Guillaume Emeriaud, MD PhD
- Numéro de téléphone: 5143454708
- E-mail: guillaume.emeriaud@umontreal.ca
Sauvegarde des contacts de l'étude
- Nom: Lucy Clayton, MSc
- E-mail: lucy.clayton.hsj@ssss.gouv.qc.ca
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada
- Alberta Children's Hospital
-
Contact:
- Laurie Lee, NPS PhD
- Numéro de téléphone: 4032206546
- E-mail: laurie.lee@ucalgary.ca
-
-
Ontario
-
Ottawa, Ontario, Canada
- CHEO
-
Contact:
- Dayre McNally, MD
- Numéro de téléphone: 6137377600
- E-mail: dmcnally@cheo.on.ca
-
-
Quebec
-
Montreal, Quebec, Canada
- Montreal Children's Hospital
-
Contact:
- Patricia Fontela, MD PhD
- Numéro de téléphone: 22855 5144124400
- E-mail: patricia.fontela.med@ssss.gouv.qc.ca
-
Montreal, Quebec, Canada
- CHU Sainte Justine
-
Contact:
- Guillaume Emeriaud, MD PhD
- Numéro de téléphone: 5143454708
- E-mail: guillaume.emeriaud@umontreal.ca
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Infants younger than 2 years old
- admitted to the PICU (or managed by the PICU team while awaiting PICU admission)
- with a clinical diagnosis of bronchiolitis according to the treating team
- requiring NIV support higher than CPAP/HFNC according to the treating team, a criteria present for less than 8 hours.
Exclusion Criteria:
- imminent intubation criteria
- refusal by the physician in charge
- chronic home ventilation
- hemodynamic instability requiring vasopressors
- contraindication to NIV or to gastric tube insertion
- patients in whom a limitation of life-support treatment is considered
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: NIV-NAVA arm
Installation of an Edi catheter. Ventilation with NIV-NAVA as long as a bi-level NIV support is needed. |
Non-invasive support using NAVA technology |
|
Aucune intervention: Control arm (usual care)
Ventilation according to the clinical team. No NAVA ventilation allowed. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recruitment rate
Délai: from initiation to the end of the 6-month study enrolment period
|
% of eligible patients (identified by screening) who are included in the study at each site and overall |
from initiation to the end of the 6-month study enrolment period
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
adherence to the intervention
Délai: during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
In the NAVA arm : % of patients who receive at least 2 hours of NIV-NAVA support, within 2 hours after randomization. In control arm: absence of NAVA use |
during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
|
completion of the definitive trial outcomes
Délai: from initiation to the end of the 6-month study enrolment period
|
completion of the definitive trial outcomes : measurement of intubation rate, duration of ventilatory support, length of PICU and hospital stays |
from initiation to the end of the 6-month study enrolment period
|
|
Evolution of the respiratory distress mWCAS score
Délai: at randomization, and after 2, 6, and 24 hours
|
Evolution of mWCAS |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the respiratory distress ROX-HR score
Délai: at randomization, and after 2, 6, and 24 hours
|
Evolution of ROX-HR scores |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the comfort score
Délai: at randomization, and after 2, 6, and 24 hours
|
Evolution of the comfort score (FLACC) |
at randomization, and after 2, 6, and 24 hours
|
|
Capacity to assess the evolution at 3 months post PICU
Délai: 3 months post PICU discharge
|
Percentage of patients with assessment of PICS-p at 3 months post discharge |
3 months post PICU discharge
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Guillaume Emeriaud, MD PhD, CHU Sainte Justine, Université de Montréal
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MP-21-2027-10447
- 583747 (Autre subvention/numéro de financement: CIHR)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
This is a pilot study. If the pilot shows feasibility of a larger trial with no change in the protocol, we may continue the trial with the same protocol and enroll the subjects from the pilot within the larger trial (Vanguard).
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .